Structure-based macrocyclization yields hepatitis C virus NS5B inhibitors with improved binding affinities and pharmacokinetic properties (Q27678311)

20

Pierre Raboisson

0 references

Tse-I Lin

2

Tse-I Lin

0 references

Origène Nyanguile

18

Origène Nyanguile

0 references

Benoit Devogelaere

8

Benoit Devogelaere

0 references

Maxwell D Cummings

1

Maxwell D Cummings

0 references

Pascale Dehertogh

12

Pascale Dehertogh

0 references

Sandrine Vendeville

21

Sandrine Vendeville

0 references

Erna Cleiren

14

Erna Cleiren

0 references

Abdellah Tahri

4

Abdellah Tahri

0 references

Katie Amssoms

6

Katie Amssoms

0 references

Stefaan Last

7

Stefaan Last

0 references

Marie-Claude Rouan

9

Marie-Claude Rouan

0 references

Jan Martin Berke

11

Jan Martin Berke

0 references

Els Fransen

13

Els Fransen

0 references

Liesbet van der Helm

15

Liesbet van der Helm

0 references

Kristof Van Emelen

17

Kristof Van Emelen

0 references

Kenny Simmen

19

Kenny Simmen

0 references

author name string

Lili Hu

3

0 references

David McGowan

5

0 references

Gregory Fanning

Angewandte Chemie International Edition

16

0 references

language of work or name

English

0 references

publication date

7 May 2012

0 references

published in

0 references

volume

51

0 references

issue

19

0 references

page(s)

4637-40

0 references

cites work

The exploration of macrocycles for drug discovery--an underexploited structural class

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201200110

Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201200110

Conformational flexibility, internal hydrogen bonding, and passive membrane permeability: successful in silico prediction of the relative permeabilities of cyclic peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201200110

What can a chemist learn from nature's macrocycles?--a brief, conceptual view.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201200110

Interdomain communication in hepatitis C virus polymerase abolished by small molecule inhibitors bound to a novel allosteric site

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201200110

Discovery of conformationally constrained tetracyclic compounds as potent hepatitis C virus NS5B RNA polymerase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201200110

Tetracyclic indole inhibitors of hepatitis C virus NS5B-polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201200110

Potent inhibitors of subgenomic hepatitis C virus RNA replication through optimization of indole-N-acetamide allosteric inhibitors of the viral NS5B polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201200110

Improved replicon cellular activity of non-nucleoside allosteric inhibitors of HCV NS5B polymerase: from benzimidazole to indole scaffolds.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201200110

Development of carboxylic acid replacements in indole-N-acetamide inhibitors of hepatitis C virus NS5B polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201200110

Discovery of pentacyclic compounds as potent inhibitors of hepatitis C virus NS5B RNA polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201200110

Acyl glucuronide reactivity in perspective: biological consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201200110

Preclinical pharmacokinetics and metabolism of a potent non-nucleoside inhibitor of the hepatitis C virus NS5B polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201200110

N-Acetamideindolecarboxylic acid allosteric 'finger-loop' inhibitors of the hepatitis C virus NS5B polymerase: discovery and initial optimization studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201200110

Crystal structures of the RNA-dependent RNA polymerase genotype 2a of hepatitis C virus reveal two conformations and suggest mechanisms of inhibition by non-nucleoside inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201200110

Discovery of (7R)-14-cyclohexyl-7-{[2-(dimethylamino)ethyl](methyl) amino}-7,8-dihydro-6H-indolo[1,2-e][1,5]benzoxazocine-11-carboxylic acid (MK-3281), a potent and orally bioavailable finger-loop inhibitor of the hepatitis C virus NS5B polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201200110

An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201200110

Molecular modeling based approach to potent P2-P4 macrocyclic inhibitors of hepatitis C NS3/4A protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201200110

The influence of drug-like concepts on decision-making in medicinal chemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201200110

What do medicinal chemists actually make? A 50-year retrospective

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201200110

Ruthenium-based heterocyclic carbene-coordinated olefin metathesis catalysts

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201200110

Metal-mediated synthesis of medium-sized rings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201200110

Drug-target residence time and its implications for lead optimization

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201200110

Rate-limited steps of human oral absorption and QSAR studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201200110